Institut Curie, CNRS-UMR3244, Sorbonne University, 75005 Paris, France.
Present addresses: Cancer Genomics lab, Inserm-U981, Gustave Roussy Cancer Center Grand Paris, Villejuif, 94805, France.
Mol Biol Cell. 2024 Dec 1;35(12):ar151. doi: 10.1091/mbc.E24-08-0370. Epub 2024 Nov 6.
Epithelial-to-mesenchymal transition (EMT) allows cancer cells to metastasize while acquiring resistance to apoptosis and chemotherapeutic agents with significant implications for patients' prognosis and survival. Despite its clinical relevance, the mechanisms initiating EMT during cancer progression remain poorly understood. We demonstrate that DNA damage triggers EMT and that activation of poly (ADP-ribose) polymerase (PARP) and the PARP-dependent chromatin remodeler ALC1 (CHD1L) was required for this response. Our results suggest that this activation directly facilitates access to the chromatin of EMT transcriptional factors (TFs) which then initiate cell reprogramming. We also show that EMT-TFs bind to the RAD51 promoter to stimulate its expression and to promote DNA repair by homologous recombination. Importantly, a clinically relevant PARP inhibitor reversed or prevented EMT in response to DNA damage while resensitizing tumor cells to other genotoxic agents. Overall, our observations shed light on the intricate relationship between EMT, DNA damage response, and PARP inhibitors, providing potential insights for in cancer therapeutics.
上皮-间充质转化(EMT)使癌细胞能够转移,同时获得对细胞凋亡和化疗药物的耐药性,这对患者的预后和生存有重大影响。尽管 EMT 具有临床相关性,但在癌症进展过程中引发 EMT 的机制仍知之甚少。我们证明 DNA 损伤引发 EMT,并且聚(ADP-核糖)聚合酶(PARP)和 PARP 依赖性染色质重塑因子 ALC1(CHD1L)的激活是这种反应所必需的。我们的结果表明,这种激活直接促进 EMT 转录因子(TFs)进入染色质,然后启动细胞重编程。我们还表明,EMT-TFs 结合 RAD51 启动子以刺激其表达,并通过同源重组促进 DNA 修复。重要的是,一种临床相关的 PARP 抑制剂可逆转或阻止 DNA 损伤后的 EMT,同时使肿瘤细胞对其他遗传毒性药物敏感。总的来说,我们的观察结果揭示了 EMT、DNA 损伤反应和 PARP 抑制剂之间复杂的关系,为癌症治疗提供了潜在的见解。